Aligos Therapeutics Inc (ALGS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.02+5.68%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ALGS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -32.0% |
| Our one-year growth estimate | diamond | -11.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 20.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ALGS — litigation filed
Dated 2026-04-21
Entry into a Material Definitive Agreement. On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosa…
Why it matters: Aligos said its cash would fund planned work through Q4 2026. Its next update can show whether new funds are needed.
Worry ifThe next report shows cash and investments, or new funding, enough to cover planned work beyond Q4 2026.
Less concerning ifThe next report says cash is not enough to fund planned work, or shows no new funding after the Q4 2026 runway ends.
Why it matters: The trial tests whether pevifoscorvir sodium lowers HBV DNA more than tenofovir. A strong result would support more development.
Watch forTopline results meet the main HBV DNA goal in both groups, HBeAg+ and HBeAg-.
Also watch forResults miss the main HBV DNA goal in either group, or the company delays the readout beyond late Q3 2027.
Why it matters: A trial start would move Aligos's HBV drug from lab work into human testing. Amoytop is funding work in China.
Supportive ifAmoytop starts the planned Phase 1 SAD/MAD study in healthy volunteers in China.
Worry ifAmoytop has not started the Phase 1 study by the next company update, or says the study is delayed.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $828 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,931 loss on $10,000 · 69.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.